The effect of two different doses of aprotinin on hemostasis in cardiopulmonary bypass surgery: similar transfusion requirements and blood loss.
暂无分享,去创建一个
J. Fontcuberta | J. Souto | J. Mateo | A. Santamaría | H. Litvan | A. Oliver | Joaquín Murillo | J. Murillo | J. Mateo | Amparo Santamaría | Héctor Litvan | J. Souto
[1] K. Hatakeyama,et al. Fibrin-Rich and Platelet-Rich Thrombus Formation on Neointima: Recombinant Tissue Factor Pathway Inhibitor Prevents Fibrin Formation and Neointimal Development following Repeated Balloon Injury of Rabbit Aorta , 1998, Thrombosis and Haemostasis.
[2] M. Ray,et al. Aprotinin Reduces Blood Loss after Cardiopulmonary Bypass by Direct Inhibition of Plasmin , 1997, Thrombosis and Haemostasis.
[3] N. Hayashida,et al. Effects of minimal-dose aprotinin on coronary artery bypass grafting. , 1997, Journal of Thoracic and Cardiovascular Surgery.
[4] L. Reilly,et al. A blinded trial of local recombinant tissue factor pathway inhibitor versus either local or systemic heparin in a vein bypass model. , 1997, Journal of vascular surgery.
[5] A. Siegbahn,et al. Monocyte tissue factor expression, cell activation, and thrombin formation during cardiopulmonary bypass: a clinical study. , 1997, The Journal of thoracic and cardiovascular surgery.
[6] J. Copeland,et al. Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens. , 1996, The Annals of thoracic surgery.
[7] L. Cohn,et al. Aprotinin in primary valve replacement and reconstruction: a multicenter, double-blind, placebo-controlled trial. , 1996, The Journal of thoracic and cardiovascular surgery.
[8] A. Sturk,et al. Low-dose and high-dose aprotinin improve hemostasis in coronary operations. , 1996, The Journal of thoracic and cardiovascular surgery.
[9] G. Schmitz,et al. Aprotinin Has no Effect on Platelet Activation and Adhesion during Cardiopulmonary Bypass , 1996, Thrombosis and Haemostasis.
[10] T. Shankey,et al. Aprotinin modulation of platelet activation in patients undergoing cardiopulmonary bypass operations. , 1996, The Annals of thoracic surgery.
[11] R. E. Clark,et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. , 1995, Circulation.
[12] J. Fontcuberta,et al. Aprotinin versus desmopressin for patients undergoing operations with cardiopulmonary bypass. A double-blind placebo-controlled study. , 1995, The Journal of thoracic and cardiovascular surgery.
[13] D. Roberts,et al. Half-dose aprotinin preserves hemostatic function in patients undergoing bypass operations. , 1995, The Annals of thoracic surgery.
[14] H. Teufelsbauer,et al. Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. , 1994, The Journal of thoracic and cardiovascular surgery.
[15] A. Michelson,et al. Aprotinin reduces cardiopulmonary bypass‐induced blood loss and inhibits fibrinolysis without influencing platelets , 1993, British journal of haematology.
[16] R. Colman,et al. Tissue factor is expressed on monocytes during simulated extracorporeal circulation. , 1993, Circulation research.
[17] G. Hempelmann,et al. Comparison of two aprotinin dosage regimens in pediatric patients having cardiac operations. Influence on platelet function and blood loss. , 1993, The Journal of thoracic and cardiovascular surgery.
[18] M. Jochum,et al. Hemostatic activation during cardiopulmonary bypass with different aprotinin dosages in pediatric patients having cardiac operations , 1993 .
[19] J. Soria,et al. Hemostasis in Patients Undergoing Extracorporeal Circulation: The Effect of Aprotinin (Trasylol) , 1991, Thrombosis and Haemostasis.
[20] K. M. Taylor,et al. EFFECT OF APROTININ ON NEED FOR BLOOD TRANSFUSION AFTER REPEAT OPEN-HEART SURGERY , 1987, The Lancet.
[21] J. Fontcuberta,et al. Platelet function during cardiopulmonary bypass not changed by two different doses of aprotinin. , 2000, Haematologica.
[22] M. Jochum,et al. Influence of high- and low-dose aprotinin on activation of hemostasis in open heart operations. , 1998, The Annals of thoracic surgery.
[23] K. Watterson,et al. "Low-dose" aprotinin modifies hemostasis but not proinflammatory cytokine release. , 1997, The Annals of thoracic surgery.
[24] R. Pifarré. Blood conservation with aprotinin , 1995 .
[25] R. Sapsford,et al. Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency. , 1993, The Journal of thoracic and cardiovascular surgery.
[26] Robert W. Colman. Hemostasis and thrombosis: Basic principles and clinical practice , 1987 .